Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study

被引:12
|
作者
Choi, Soojeong [1 ]
Lee, Young Jae [2 ]
Jeong, Jae Ho [3 ]
Jung, Jinhong [4 ]
Lee, Jong Won [1 ]
Kim, Hee Jeong [1 ]
Ko, Beom Seok [1 ]
Son, Byung Ho [1 ]
Ahn, Sei Hyun [1 ]
Lee, Yura [1 ,5 ]
Chung, Il Yong [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Obstet & Gynecol, Kangnung, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med Informat, Seoul, South Korea
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
breast neoplasms; dilatation and curettage; gynecological examination; tamoxifen; endometrial neoplasms; SURGICAL ADJUVANT BREAST; ENDOCRINE THERAPY; LONG-TERM; WOMEN; PREVENTION; SOCIETY;
D O I
10.3389/fonc.2021.636378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Although the guidelines recommend gynecological assessment and close monitoring for symptoms of endometrial cancer in postmenopausal breast cancer survivors taking tamoxifen (TAM), the risk of endometrial cancer in young breast cancer survivors has not yet been fully assessed. This study aimed to investigate the risk of developing endometrial cancer and the frequencies of gynecological examinations in young breast cancer survivors taking TAM in South Korea. Methods A nationwide retrospective cohort study was conducted using the Health Insurance Review and Assessment Service claims data. Kaplan-Meier analyses and log-rank tests were used to assess the probability of endometrial cancer, benign endometrial conditions, and the probability of invasive endometrial procedure. To analyze the risk of endometrial cancer and benign endometrial conditions, we used a multivariable Cox proportional hazards regression model. Results Between 2010 and 2015, 60,545 newly diagnosed female breast cancer survivors were included. The total person-years were 256,099 and 140 (0.23%) patients developed endometrial cancer during the study period. In breast cancer survivors aged >= 60 years [hazard ratio (HR), 5.037; 95% confidence interval (CI), 2.185-11.613], 50-59 years (HR, 4.343; 95% CI, 2.122-8.891), and 40-49 years (HR, 2.121; 95% CI, 1.068-4.213), TAM was associated with an increased risk of endometrial cancer. In subjects aged below 40 years, TAM did not significantly increase the risk of endometrial cancer. However, among the TAM subgroups, breast cancer survivors aged below 40 years [1.61 per 1,000 person-years (PY); HR, 12.460; 95% CI, 2.698-57.522] and aged 40-49 years (2.22 per 1,000 PY; HR, 9.667; 95% CI, 4.966-18.819) with TAM-related endometrial diseases showed significantly increased risks of endometrial cancer. Among the TAM subgroup with benign endometrial conditions, the ratios of the frequency of invasive diagnostic procedures to the incidence of endometrial cancer were higher in subjects under 40 than subjects aged 60 or more. Conclusion Young breast cancer survivors with TAM-related benign endometrial diseases are at a higher risk of developing endometrial cancer. Gynecological surveillance should be tailored to the risk of endometrial cancer in young breast cancer survivors to improve the early detection of endometrial cancer and avoid unnecessary invasive procedures.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Endometrial Cancer Incidence in Breast Cancer Patients Correlating with Age and Duration of Tamoxifen Use: a Population Based Study
    Chen, Ju-Yin
    Kuo, Shou-Jen
    Liaw, Yung-Po
    Avital, Itzhak
    Stojadinovic, Alexander
    Man, Yan-gao
    Mannion, Ciaran
    Wang, Jianlian
    Chou, Ming-Chih
    Tsai, Horng-Der
    Chen, Shou-Tung
    Hsiao, Yi-Hsuan
    JOURNAL OF CANCER, 2014, 5 (02): : 151 - 155
  • [42] Risk of endometrial cancer in breast cancer patients under long-term adjuvant treatment with tamoxifen
    Cecchini, S
    Ciatto, S
    Bonardi, R
    Mazzotta, A
    Pacini, P
    Muraca, MG
    Zappa, M
    TUMORI JOURNAL, 1998, 84 (01): : 21 - 23
  • [43] Endometrial cancer after Tamoxifen treatment of breast cancer. Results of a retrospective cohort study
    Vrscaj, MU
    Bebar, S
    Djurisic, A
    Fras, PA
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 1999, 20 (01) : 20 - 25
  • [44] Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen
    Biron-Shental, T
    Tepper, R
    Fishman, A
    Shapira, J
    Cohen, I
    GYNECOLOGIC ONCOLOGY, 2003, 90 (02) : 382 - 386
  • [45] Endometrial cancers in postmenopausal breast cancer patients with tamoxifen treatment
    Cohen, I
    Azaria, R
    Fishman, A
    Tepper, R
    Shapira, J
    Beyth, Y
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1999, 18 (04) : 304 - 309
  • [46] Rapamycin inhibits tamoxifen-induced endometrial proliferation in vitro as a pilot approach for endometrial protection in breast cancer
    Nakamura, Akiko
    Tanaka, Yuji
    Amano, Tsukuru
    Takebayashi, Akie
    Takahashi, Akimasa
    Hanada, Tetsuro
    Yoneoka, Yutaka
    Tsuji, Shunichiro
    Murakami, Takashi
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [47] Hysteroscopic Endometrial Resection in Women Treated With Tamoxifen for Breast Cancer Provides Definitive Diagnosis and Effective Long-Term Therapy
    Vilos, George A.
    Alzawawi, Nabigah
    Oraif, Ayman
    Lam, Jennifer S.
    Badeghiesh, Ahmad
    Abu-Rafea, Basim
    Vilos, Angelos G.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2022, 44 (05) : 517 - 520
  • [48] Endometrial cancer within tamoxifen-related polyps in patients with breast cancer
    Tate, S
    Yamazawa, K
    Sekiya, S
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2004, 83 (08) : 769 - 770
  • [49] Endometrial carcinoma in tamoxifen-treated breast cancer patient: Clinicopathological, immunohistochemical, and genetic analysis
    Esteller, M
    Garcia, A
    Martinez-Palones, JM
    Xercavins, J
    Reventos, J
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1999, 18 (04) : 387 - 391
  • [50] DNA-CONTENT IN ENDOMETRIAL CARCINOMA OF TAMOXIFEN-TREATED BREAST-CANCER PATIENTS
    MOBERGER, B
    FORNANDER, T
    HELLSTROM, AC
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1994, 4 (02) : 131 - 134